Latest Articles
In silico evaluation of procyanidin as a potential ESR1 inhibitor: docking and MD insights in uterine fibroids and endometriosis.
These are two of the most common gynecologic diseases, affecting 15% to 80% of women of childbearing age diseases. The existing treatments, such as hormonal drugs and selective estrogen receptor …
Published: Jan. 14, 2026, midnight
[Current and future medical treatment for endometriosis].
Endometriosis is a chronic, progressive inflammatory disease that occurs in approximately 10% of women of reproductive age, resulting in a decreased quality of life due to dysmenorrhea, chronic pain, and …
Published: Nov. 6, 2024, midnight
SR-16234, a Unique Selective Estrogen Receptor Modulator, Suppressed Proliferation and Pain-Related Factor Expression by Inhibition of the Nuclear Factor-kappa B Pathway in Endometriotic Stromal Cells.
What is the effect of SR-16234 (SR), a selective estrogen receptor (ER) modulator, on human endometriotic stromal cells (ESCs)?
Published: Oct. 31, 2024, midnight
Link copied to clipboard!